Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML.
Targeting of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung cancer. Study published in “Cancer Research”. These findings demonstrate that targeting MUC1-C is a novel approach for downregulating MYC expression in MYC-dependent carcinomas.
|